Erika Hamilton, MD

Erika Hamilton, MD, is the director of breast cancer research at Sarah Cannon Research Institute.

Articles by Erika Hamilton, MD

TROP2 ADC Shows Promise in Pretreated TNBC: Erika Hamilton, MD

December 8th 2025

Erika Hamilton, MD, reports early trial data showing DB-1305/BNT325, a TROP2-targeted ADC, produced encouraging responses in heavily pretreated TNBC patients.

New TROP2-Targeted ADC Shows Promise in TNBC: Erika Hamilton, MD

BySabrina McCrear,Erika Hamilton, MD

December 5th 2025

A new TROP2-targeted ADC showed promising efficacy in an early TNBC trial, with Erika Hamilton, MD, highlighting its potential for broader use in future treatment.

Erika Hamilton, MD

Articles by Erika Hamilton, MD

TROP2 ADC Shows Promise in Pretreated TNBC: Erika Hamilton, MD

New TROP2-Targeted ADC Shows Promise in TNBC: Erika Hamilton, MD

Latest Updated Articles

Trending on AJMC

FDA to Accept Deidentified Real-World Evidence for Select Medical Device Applications

FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Metastatic HER2-Positive Breast Cancer

ACA Subsidy Expiration Raises Concerns for Behavioral Health Access and ED Strain

HIV in 2025 Defined by Challenges Throughout the Year, Despite Some Advances

ICYMI: Highlights From WCLC 2025